Backgrounds/Aims: Identifying pancreatic cancer patients at high risk of early mortality following surgical resection for pancreatic cancer is important to make optimal treatment decisions in multidisciplinary setting. The purpose of this study was to identify the factors related to early mortality in patients who underwent pancreatic resection for pancreatic adenocarcinoma. Methods: We reviewed our institution's experience with all consecutive patients who underwent pancreatectomy for pancreatic adenocarcinoma from January 2000 to December 2010. One thousand patients were eligible for our study. Fifty-three patients who did not meet the study criteria were excluded. Based on 12 months after surgery, patients were divided into early mortality group or the remaining group. We performed logistic regression analysis to identify predictors of early mortality. Results: Among 947 patients who met our study criteria, 302 (31.9%) early mortality (defined as experiencing death within 12 months after surgery) occurred. Multivariate analysis revealed that patient age and surgery time period were statistically significant predictors of early mortality within six months after surgery. Poorly differentiated tumor and adjuvant chemotherapy were statistically significant predictors of early mortality within 12 months after surgery. Total pancreatectomy and lymphovascular invasion were significant (p＜0.05) prognostic factors of early mortality within 6 or 12 months after surgery. Conclusions: We suggest followings to avoid early mortality after pancreatic resection: patients with multiple risk factors related to early mortality after pancreatectomy should be considered for alternative treatment; patient's general condition and surgical technique improvement are important; and adjuvant therapy should be taken into consideration. 
INTRODUCTION
Pancreatic cancer remains a lethal disease. It has high mortality rate due to the aggressive nature of the tumor and its asymptomatic disease progression leading to delayed diagnosis. Pancreatic cancer has an estimated 20% resectability at diagnosis and an overall five-year survival of 5%. [1] [2] [3] Surgery remains the only curative treatment. Complete pancreatic resection showed actuarial five-year survival rates of 15-25% following pancreaticoduodenectomy 4-6 and 8-14%
following distal pancreatectomy. 7, 8 The common causes of treatment failure after pancreatic cancer resection have been locoregional recurrence and/or the development of distant metastases. The persistence or recurrence of locoregional disease has been discovered in as many as 80% of patients who has undergone curative resection. 9 Cumulative survival curve after resection for pancreatic cancer shows a rapid decline pattern during the early postoperative period followed by a subtle downward pattern.
Such early mortality after pancreatectomy may be attributed to inadequate pre-or intraoperative tumor staging, the very aggressive nature of the disease, surgery-related factors, or unknown causes. Identifying patients at high risk for early mortality is important to make the optimal decision regarding the most appropriate treatment for these patients before surgery.
A few studies described early mortality of patients following pancreatic surgery for pancreatic cancer. [10] [11] [12] Tumor staging according to the AJCC 7th edition staging guidelines. PD, pancreaticoduodenectomy; TP, total pancreatectomy; DM, diabetes mellitus; HTN, hypertension However, high-volume study has not been reported.
Therefore, the objective of this study was to identify the characteristics related to early mortality in patients who has undergone pancreatic resection for pancreatic adenocarcinoma in a high-volume population. We defined postoperative mortality as in-hospital deaths related to surgery. Five study patients died due to postoperative mortality. Table 1 shows the information and cause of death of patients with surgery-related mortality. In the study group, there were four cases of non-disease-related death, including asphyxia (n=1), pneumonia (n=1), cerebral infarction (n=1), and opioid overuse (n=1). Data from patients who died due to surgery-related cause (n=5) or non-disease-related causes (n=4) were excluded from this study. Stage IV disease patients with distant metastasis at the time of their surgery (n=44) were also excluded. Therefore, a total of 947 patients were included in our analysis.
MATERIALS AND METHODS

Study population
There is no clear definition or consensus regarding early mortality after pancreatic surgery for pancreatic cancer.
We arbitrarily defined early mortality as death within 12 months after pancreatectomy which has been used in other published studies.
9,11
Patient characteristics
Medical records of patients were retrospectively 
RESULTS
Survival outcome
The median follow-up for our study population (n=947) was 19.0 months. The median disease-specific survival was 18.6 months. The cumulative survival curve of the study population is shown in Fig. 1 . Median disease-specific sur- Log-rank test revealed statistically significant (p＜0.001) difference in survival among the three groups. The one-, two-, and five-year survival rates were also improved according to the time period of surgery performed (Table 2) .
Among the 947 patients, 302 (31.9%) had early-mortality (died within 12 months after the surgery), including 235 (77.8%) who died between 6 and 12 months after surgery, which was at least three times of mortality occurred The pre-and postoperative characteristics and their association with early mortality within 6 months following surgery are summarized in Table 3 . When the 6-month period was compared to 12 months after resection of pancreatic adenocarcinoma, the following was found to be associated with early mortality within 6 months after surgery: age, preoperative albumin≤3.3 g/dl, total pancreatectomy, the postoperative hospital stay, poorly differentiated tumor, and lymphovascular invasion. In addition to symptoms, the followings were also risk factors associated with early mortality during the first 12 months after surgery: preoperative CA19-9 ＞37 U/ml, preoperative hemoglobin ≤13 g/dl, (Table 4) .
Multivariate analysis of the prognostic factors associated with early mortality
A multivariate logistic regression analysis was performed with significant predictors of survival in the univariate analysis. The multivariate analysis results showed a different pattern of risk factors associated mortality between the 6-month and 12-month periods after surgery.
During the 6-month period, patient age and time of surgery were statistically significant (p＜0.05) risk factors related to early mortality. On the contrary, poorly differentiated tumor and adjuvant chemotherapy were statistically significant (p＜0.05) risk factors related to early mortality during the 12-month period. Total pancreatectomy and lymphovascular invasion were significant (p＜0.05) prognostic factors of early mortality during both time periods (Table 5) .
DISCUSSION
Pancreatic cancer, including pancreatic adenocarcinoma, remains a lethal disease. Surgical resection is the only curative treatment for locally advanced disease. In general, the survival curve of malignant diseases with poor prognosis shows a rapid downward pattern during the early postoperative period, which is also the case in pancreatic adenocarcinoma. Despite numerous studies and efforts over the last several decades, we did not note a dramatic improvement in pancreatic cancer survival rate.
Many pancreatic adenocarcinoma patients died during the early postoperative period despite curative resection.
In our study, 67 (7.1%) and 302 (31.9%) patients died within 6 and 12 months following pancreatic resection, respectively. Other studies have shown similar outcomes, with up to 30% of patients died within 12 months after resection. 12, 13 If we can identify the risk factors related to early mortality after resection, we may be able to consider alternative treatment rather than up-front surgery in patients predicted to have a very high postoperative mortality rate. If we can correct the risk factors related to early mortality, we may be able to improve patient survival outcome related to early mortality and/or overall survival.
Therefore, the purpose of this study is to identify the risk factors related to early mortality in patients undergoing pancreatic resection for pancreatic adenocarcinoma. Total pancreatectomy and lymphovascular invasion were significant prognostic factors of early mortality in both the 6-and 12-month periods after surgery. It is noteworthy that TNM staging, including positive lymph nodes and tumor size, were not associated with early mortality.
In the 6-month period after resection, patient age was associated with increased risk of early mortality, suggesting that patient's general health condition and performance status may affect the mortality rate during the early postoperative period. On univariate analysis, a low preoperative albumin level (≤3.3 g/dl) was a risk factor related to possible 6-and 12-month early mortality (p ＜0.01), indicating that a patient's poor nutritional status might increase the early mortality rate following resection.
In our study, C-reactive protein serum level was not examined. In several studies, the Glasgow prognostic score was proven to be a prognostic factor for pancreatic cancer. [14] [15] [16] It will be useful to apply the Glasgow prognostic score system in future research regarding early mortality. According to time of surgery, the patient sur- In a study regarding early mortality after pancreaticoduodenectomy or total pancreatectomy for pancreatic adenocarcinoma, patient age, poorly differentiated tumor, and adjuvant chemoradiation therapy were statistically significant prognostic factors associated with early mortality defined as nine months after surgery. 10 The duration of symptoms prior to surgery were shown to predict early mortality as determined in another study. However, such information was not available in our study. There are only a few research studies describing early mortality after pancreatic resection for pancreatic cancer. [10] [11] [12] To our knowledge, this study is the largest series regarding early mortality after pancreatic resection for pancreatic adenocarcinoma. Further prospective studies will be needed in the future. Recently, laparoscopic pancreatectomy including robot-assisted pancreatectomy has been increasingly performed for pancreas cancer patients.
In order to determine whether minimally invasive surgeries can decrease early mortality after pancreatectomy, more studies are needed.
In summary, pancreatic cancer including pancreatic adenocarcinoma remains a lethal disease, with a high early mortality rate after surgery up to 30% within 12 months following surgery. Early mortality after pancreatic resection is associated with factors other than TNM staging.
To overcome early mortality after pancreatic resection, patients with multiple risk factors related to early mortality after pancreatectomy should be considered for alternative treatment. In particular, total pancreatectomy should be very carefully selected for patients with regard to the surgical risks and benefits. A patient's general condition and potential surgical technique improvement are important. If necessary, more aggressive nutritional and general condition correction should be performed before surgery. In addition, strategies to suppress the tumor such as chemotherapy are also necessary.
